<p>Syndax Pharmaceuticals (SNDX) 在 ASH 會議上展示了最新的 Revuforj 數據，這一更新的療效和安全性圖景正是讓投資者重新思考該股票長期潛力的原因。</p>
<p>請查看我們對 Syndax Pharmaceuticals 的最新分析。</p>
<p>在這一穩定的臨牀進展的推動下，該股票悄然重新定價，過去一個月的股價回報為 24.11%，年初至今的股價回報為 38.57%，儘管三年期的總股東回報仍為負值。這表明，隨着投資者重新評估增長前景和風險特徵，動能正在重建。</p>
<p>如果 Revuforj 的故事讓你更廣泛地關注腫瘤學和罕見疾病的股票，現在可能是探索其他潛在贏家的好時機。</p>
<p>然而，儘管 Revuforj 的臨牀驗證不斷增強，股價仍以大幅低於分析師目標的內在價值交易，Syndax 是否是一個被低估的成長故事，還是投資者已經將下一輪上漲的預期納入考慮？</p>
<h2>最受歡迎的敍述：50.4% 被低估</h2>
<p>敍述的公允價值設定在接近 39 美元，而最後收盤價為 19.51 美元，這一差距突顯了未來增長模型的激進性。</p>
<blockquote>
<p><em>晚期管線進展（包括前線試驗、生命週期管理以及向新適應症如 Niktimvo 的 IPF 擴展），結合強勁的臨牀數據和在精準腫瘤學中的市場領先地位，提供了與對創新、靶向療法需求激增相一致的強勁長期增長途徑，支持持續的多年度盈利動能。</em></p>
</blockquote>
<p>閲讀完整敍述。</p>
<p>想知道什麼樣的收入激增和利潤重置能夠證明這種上漲的合理性，以及未來的收益倍數如何將這一切聯繫在一起？完整的敍述對此進行了詳細分析。</p>
<p><strong>結果：公允價值為 39.31 美元（被低估）</strong></p>
<p>完整閲讀敍述，瞭解預測背後的原因。</p>
<p>然而，這一敍述依賴於 Revuforj 和 Niktimvo 的完美執行，安全性認知、標籤延遲或更強的競爭對手可能迅速侵蝕這一上漲空間。</p>
<p>瞭解 Syndax Pharmaceuticals 敍述的關鍵風險。</p>
<h2>另一種看待價值的方式</h2>
<p>雖然敍述框架將 Syndax 標記為顯著被低估，但簡單的銷售基礎視角卻講述了一個截然不同的故事。該股票的銷售倍數為 15.2 倍，而美國生物技術行業為 12.1 倍，同行為 11.1 倍，尤其是與僅 1.3 倍的公允比率相比，該股票看起來被高估了。</p>
<p>這一差距表明，投資者已經為未來的增長支付了豐厚的溢價。這引發了一個問題：這是一個定價錯誤的寶石，還是一個等待回調的擁擠動量交易？</p>
<p>查看數字對這一價格的看法——在我們的估值分析中瞭解更多。</p>
<p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/55fa61da-ae1f-4d19-814f-da38552d6ebf/chart/ps-multiple-vs-industry?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/55fa61da-ae1f-4d19-814f-da38552d6ebf/chart/ps-multiple-vs-industry"/></p>
<p>NasdaqGS:SNDX 截至 2025 年 12 月的 PS 比率</p>
<h2>自己構建 Syndax Pharmaceuticals 敍述</h2>
<p>如果這個視角與您的觀點不符，或者您更願意依賴自己的分析，您可以在三分鐘內構建一個新的敍述：按照您的方式。</p>
<p>一個好的起點是我們的分析，強調投資者對 Syndax Pharmaceuticals 的兩個關鍵回報的樂觀預期。</p>
<h2>尋找更多投資想法？</h2>
<p>在市場充滿定價錯誤的機會時，不要止步於一個引人注目的論點。使用這些專注的工具來提升您的下一步行動。</p>
<ul>
<li>通過掃描這些 3595 只財務狀況良好的便士股票，儘早捕捉潛在的多倍收益，這些股票的股價微小，且資產負債表強勁，基本面改善。</li>
<li>通過瞄準這 26 只處於人工智能突破與可擴展商業模式交匯點的 AI 便士股票，乘勢而上，享受結構性科技的順風。</li>
<li>通過篩選這些 900 只被低估的股票，基於現金流的交易價格顯著低於其內在價值估計，探索潛在的未來現金流引擎。</li>
</ul>
<p><em>本文由 Simply Wall St 撰寫，內容具有一般性。<strong>我們基於歷史數據和分析師預測提供評論，僅使用無偏見的方法，我們的文章不構成財務建議。</strong> 這並不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們旨在為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>

Syndax制藥

<p>Syndax 製藥（SNDX）在 ASH 會議上展示了新的 Revuforj 數據，提升了投資者的興趣，導致其股價在一個月內上漲了 24.11%。儘管三年回報為負，該股票被視為被低估，合理價值為 39.31 美元，而最後收盤價為 19.51 美元。敍述表明強勁的增長潛力，但也強調了安全感知和競爭等風險。該股票的高銷售比率引發了對其估值的質疑。Simply Wall St 提供了分析，但不提供財務建議</p>

<p>Syndax Pharmaceuticals (SNDX) just put fresh Revuforj data center stage at the ASH meeting, and that updated efficacy and safety picture is exactly what has investors rethinking the stock’s longer term potential.</p>
<div class="lb-trans"><p>Syndax Pharmaceuticals (SNDX) 在 ASH 會議上展示了最新的 Revuforj 數據，這一更新的療效和安全性圖景正是讓投資者重新思考該股票長期潛力的原因。</p>
</div><p>See our latest analysis for Syndax Pharmaceuticals.</p>
<div class="lb-trans"><p>請查看我們對 Syndax Pharmaceuticals 的最新分析。</p>
</div><p>The stock has quietly rerated on the back of this steady clinical drumbeat, with a 1 month share price return of 24.11 percent and a year to date share price return of 38.57 percent, even though the 3 year total shareholder return remains negative. This suggests momentum is rebuilding as investors reassess both the growth runway and risk profile.</p>
<div class="lb-trans"><p>在這一穩定的臨牀進展的推動下，該股票悄然重新定價，過去一個月的股價回報為 24.11%，年初至今的股價回報為 38.57%，儘管三年期的總股東回報仍為負值。這表明，隨着投資者重新評估增長前景和風險特徵，動能正在重建。</p>
</div><p>If Revuforj’s story has you looking more broadly at oncology and rare disease names, it could be a good moment to explore other potential winners among healthcare stocks.</p>
<div class="lb-trans"><p>如果 Revuforj 的故事讓你更廣泛地關注腫瘤學和罕見疾病的股票，現在可能是探索其他潛在贏家的好時機。</p>
</div><p>Yet with shares still trading at a steep intrinsic discount to analyst targets despite Revuforj’s growing clinical validation, is Syndax an underappreciated growth story, or are investors already baking in the next leg of upside?</p>
<div class="lb-trans"><p>然而，儘管 Revuforj 的臨牀驗證不斷增強，股價仍以大幅低於分析師目標的內在價值交易，Syndax 是否是一個被低估的成長故事，還是投資者已經將下一輪上漲的預期納入考慮？</p>
</div><h2>Most Popular Narrative Narrative: 50.4% Undervalued</h2>
<div class="lb-trans"><h2>最受歡迎的敍述：50.4% 被低估</h2>
</div><p>With the narrative fair value set near $39 against a last close of $19.51, the spread highlights how aggressively future growth is being modeled.</p>
<div class="lb-trans"><p>敍述的公允價值設定在接近 39 美元，而最後收盤價為 19.51 美元，這一差距突顯了未來增長模型的激進性。</p>
</div><blockquote>
<p><em>Late-stage pipeline advancements (including frontline trials, lifecycle management, and expansion into new indications like IPF for Niktimvo), coupled with strong clinical data and market-leading positions in precision oncology, provide robust long-term growth avenues aligned with surging demand for innovative, targeted therapies, supporting sustained multi-year earnings momentum.</em></p>
</blockquote>
<div class="lb-trans"><blockquote>
<p><em>晚期管線進展（包括前線試驗、生命週期管理以及向新適應症如 Niktimvo 的 IPF 擴展），結合強勁的臨牀數據和在精準腫瘤學中的市場領先地位，提供了與對創新、靶向療法需求激增相一致的強勁長期增長途徑，支持持續的多年度盈利動能。</em></p>
</blockquote>
</div><p>Read the complete narrative.</p>
<div class="lb-trans"><p>閲讀完整敍述。</p>
</div><p>Curious what kind of revenue surge and margin reset could justify that kind of upside, and which future earnings multiple ties it all together? The full narrative breaks it down.</p>
<div class="lb-trans"><p>想知道什麼樣的收入激增和利潤重置能夠證明這種上漲的合理性，以及未來的收益倍數如何將這一切聯繫在一起？完整的敍述對此進行了詳細分析。</p>
</div><p><strong>Result: Fair Value of $39.31 (UNDERVALUED)</strong></p>
<div class="lb-trans"><p><strong>結果：公允價值為 39.31 美元（被低估）</strong></p>
</div><p>Have a read of the narrative in full and understand what's behind the forecasts.</p>
<div class="lb-trans"><p>完整閲讀敍述，瞭解預測背後的原因。</p>
</div><p>However, the narrative hinges on flawless Revuforj and Niktimvo execution, where safety perceptions, label delays, or stronger competitors could quickly erode that upside.</p>
<div class="lb-trans"><p>然而，這一敍述依賴於 Revuforj 和 Niktimvo 的完美執行，安全性認知、標籤延遲或更強的競爭對手可能迅速侵蝕這一上漲空間。</p>
</div><p>Find out about the key risks to this Syndax Pharmaceuticals narrative.</p>
<div class="lb-trans"><p>瞭解 Syndax Pharmaceuticals 敍述的關鍵風險。</p>
</div><h2>Another Way to Look at Value</h2>
<div class="lb-trans"><h2>另一種看待價值的方式</h2>
</div><p>While the narrative framework flags Syndax as significantly undervalued, a simple sales based lens tells a very different story. At 15.2 times sales versus 12.1 times for the US Biotechs industry and 11.1 times for peers, the stock looks stretched, especially against a fair ratio of just 1.3 times sales.</p>
<div class="lb-trans"><p>雖然敍述框架將 Syndax 標記為顯著被低估，但簡單的銷售基礎視角卻講述了一個截然不同的故事。該股票的銷售倍數為 15.2 倍，而美國生物技術行業為 12.1 倍，同行為 11.1 倍，尤其是與僅 1.3 倍的公允比率相比，該股票看起來被高估了。</p>
</div><p>That gap suggests investors are already paying a rich premium for future growth. This raises the question: is this a mispriced gem or a crowded momentum trade waiting for a setback?</p>
<div class="lb-trans"><p>這一差距表明，投資者已經為未來的增長支付了豐厚的溢價。這引發了一個問題：這是一個定價錯誤的寶石，還是一個等待回調的擁擠動量交易？</p>
</div><p>See what the numbers say about this price — find out in our valuation breakdown.</p>
<div class="lb-trans"><p>查看數字對這一價格的看法——在我們的估值分析中瞭解更多。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://images.simplywall.st/company/55fa61da-ae1f-4d19-814f-da38552d6ebf/chart/ps-multiple-vs-industry" alt="" original-src="https://images.simplywall.st/company/55fa61da-ae1f-4d19-814f-da38552d6ebf/chart/ps-multiple-vs-industry"/></p>
<p>NasdaqGS:SNDX PS Ratio as at Dec 2025</p>
<div class="lb-trans"><p>NasdaqGS:SNDX 截至 2025 年 12 月的 PS 比率</p>
</div><h2>Build Your Own Syndax Pharmaceuticals Narrative</h2>
<div class="lb-trans"><h2>自己構建 Syndax Pharmaceuticals 敍述</h2>
</div><p>If this perspective does not line up with your own view, or you would rather lean on your own analysis, you can craft a fresh narrative in under three minutes: Do it your way.</p>
<div class="lb-trans"><p>如果這個視角與您的觀點不符，或者您更願意依賴自己的分析，您可以在三分鐘內構建一個新的敍述：按照您的方式。</p>
</div><p>A good starting point is our analysis highlighting 2 key rewards investors are optimistic about regarding Syndax Pharmaceuticals.</p>
<div class="lb-trans"><p>一個好的起點是我們的分析，強調投資者對 Syndax Pharmaceuticals 的兩個關鍵回報的樂觀預期。</p>
</div><h2>Looking for more investment ideas?</h2>
<div class="lb-trans"><h2>尋找更多投資想法？</h2>
</div><p>Do not stop with one compelling thesis when the market is full of mispriced opportunities. Use these focused tools to sharpen your next move.</p>
<div class="lb-trans"><p>在市場充滿定價錯誤的機會時，不要止步於一個引人注目的論點。使用這些專注的工具來提升您的下一步行動。</p>
</div><ul>
<li>Capture potential multi baggers early by scanning these 3595 penny stocks with strong financials that already pair tiny share prices with balance sheet strength and improving fundamentals.</li>
<li>Ride structural tech tailwinds by targeting these 26 AI penny stocks positioned at the crossroads of artificial intelligence breakthroughs and scalable business models.</li>
<li>Explore potential future cash flow engines by filtering for these 900 undervalued stocks based on cash flows that trade at meaningful discounts to their intrinsic value estimates.</li>
</ul>
<div class="lb-trans"><ul>
<li>通過掃描這些 3595 只財務狀況良好的便士股票，儘早捕捉潛在的多倍收益，這些股票的股價微小，且資產負債表強勁，基本面改善。</li>
<li>通過瞄準這 26 只處於人工智能突破與可擴展商業模式交匯點的 AI 便士股票，乘勢而上，享受結構性科技的順風。</li>
<li>通過篩選這些 900 只被低估的股票，基於現金流的交易價格顯著低於其內在價值估計，探索潛在的未來現金流引擎。</li>
</ul>
</div><p><em>This article by Simply Wall St is general in nature. <strong>We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice.</strong> It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.</em></p>
<div class="lb-trans"><p><em>本文由 Simply Wall St 撰寫，內容具有一般性。<strong>我們基於歷史數據和分析師預測提供評論，僅使用無偏見的方法，我們的文章不構成財務建議。</strong> 這並不構成買入或賣出任何股票的推薦，也未考慮您的目標或財務狀況。我們旨在為您提供以基本數據驅動的長期分析。請注意，我們的分析可能未考慮最新的價格敏感公司公告或定性材料。Simply Wall St 在提到的任何股票中沒有持倉。</em></p>
</div>

Syndax 製藥（SNDX）在主要血液學會議上發佈強勁的新 Revuforj 數據後的估值分析